2024

Korell, F., Olson, M., Salas Benito, D., Leick, M.B., Larson, R.C., Bouffard, A.A., Silva, H., Gasparetto, A., Berger, T.R., Kann, M.C., Mergen, M., Kienka, T., Wehrli, M., Haradhvala, N., Bailey, S.R., Letai, A.G., and Maus, M.V.* Bcl-xL overexpression enhances chimeric antigen receptor (CAR) T cell proliferation and antitumor activity alone and in combination with BH3 mimetics. Accepted. Sci Trans Med.

Grauwet, K., Berger, T.R., Kann, M.C., Silva, H., Larson, R.C., Leick, M.B., Bailey, S.R., Bouffard, A.A., Grajzewski, K., Millar, D., Ghallagher, K.M.E., Turtle, C.J., Frigault, M.J., and Maus, M.V.* Stealth transgenes enable CAR-T cells to evade host immune responses. J Immunother Cancer, 2024. doi: 10.1136/jitc-2023-008417. PMID: 38724463.

Wehrli, M., Guinn, S., Birocchi, F., Kuo, A., Sun, Y., Larson, R.C., Almazan, A.J., Scarfò, I., Bouffard, A.A., Bailey, S.R., Anekal, P.V., Lopis, P.M., Nieman, L.T., Song, Y., Xu, K.H., Berger, T.R., Kann, M.C., Leick, M.B., Silva, H., Salas-Benito, D., Kienka, T., Grauwet, K., Armstrong, T.D., Zhang, R., Zhu, Q., Fu, J., Schmidts, A., Korell, F., Jan, M., Choi, B.D., Liss, A.S., Boland, G.M., Ting, D.T., Burkhar, R.A., Jenkins, R.W., Zheng, L., Jaffee, E.M., Zimmerman, J.W., and Maus, M.V.* Mesothelin CAR T-cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma. Clin Cancer Res, 2024. doi: 10.1158/1078-0432.CCR-23-3841. PMID: 38393682.

2023

Pourzia, A.L., Olson, M.L., Bailey, S.R., Boroughs, A.C., Aryal, A., Ryan, J, Maus, M.V., and Letai, A.G.* Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells. Cell Death Dis., 2023. doi: 10.1038/s41419-023-05727-x. PMID: 37055388.

2022

Bailey, S.R., Berger, T.R., Graham, C., Larson, R.C., and Maus, M.V.* Four challenges for CAR T cells to break the glass ceilings. Eur J Immunol., 2022. doi: 10.1002/eji.202250039. PMID: 36585889 All authors contributed equally.

Schmidts, A., Srivastava, A.A., Ramapriyan, R., Bailey, S.R., Bouffard, A.A., Cahill, D.P., Carter, B.S., Curry, W.T., Dunn, G.P., Frigault, M.J., Gerstner, E.R., Ghannam, J.Y., Kann, M.C., Larson, R.C., Leick, M.B., Nahed, B.V., Scarfò, I., Sun, J., Wakimoto, H., Maus, M.V., and Choi, B.D.* Tandem CAR T cells targeting EGFRvIII and IL-13Ra2 are effective against heterogenous glioblastoma. Neuro-Oncology Advances, 2022. doi: 10.1093/noajnl/vdac185.

Leick, M.B., Silva, H., Scarfò, I., Larson, R.C., Choi, B.D., Bouffard, A.A., Gallagher, K.M.E., Schmidts, A., Bailey, S.R., Kann, M.C., Jan, M., Wehrli, M., Grauwet, K., Horick, N., Frigault, M.J., and Maus, M.V.* Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell, 2022. doi: 10.1016/j.ccell.2022.04.001. PMCID: PMC9107929.

Larson, R.C., Kann, M.C., Bailey, S.R., Haradhvala, N.J., Lopis, P.M., Bouffard, A.A., Scarfò, I., Leick, M.B., Grauwet, K., Berger, T.R., Stewart, K., Anekal, P.V., Jan, M., Joung, J., Schmidts, A., Ouspenskaia, T., Law, T., Regev, A., Getz, G., and Maus, M.V.* CAR T cell killing requires the IFNgR pathway in solid but not liquid tumours. Nature, 2022. doi: 10.1038/s41586-022-04585-5. PMID: 35418687.

Bailey, S.R., Vatsa, S., Larson, R.C., Bouffard, A.A., Scarfò, I., Kann, M.C., Berger, T.R., Schimidts, A., Leick, M.B., Silva, H., Lindell, K.A., Demato, A., Gallagher, K.M.E., Frigault, M.J., and Maus, M.V.* Blockade or deletion of IFNgreduces macrophage activation and enhances CAR-T function in hematologic malignancies. Blood Cancer Discov., 2022. doi: 10.1158/2643-3230.BCD-21-0181. PMID: 35015685    *Most highly cited Blood Cancer Discoveryarticle in 2022; Winner of the Blood Cancer Discovery Award for Outstanding Journal Article.

2020

Nelson, M.H.#, Knochelmann, H.M.#, Bailey, S.R., Huff, L.W., Bowers, J.S., Majchrzak, K., Wyatt, M.M., Rubinstein, M.P., Mehrotra, S., Nishimura, M.I., Armeson, K.E., Giresi, P.G., Zilliox, M.J., Broxmeyer, H.E., and Paulos, C.M.* Identification of human CD4+ T cell populations with distinct antitumor activity. Science Advances, 2020. doi: 10.1126/sciadv.aba7443. PMCID: PMC7458458.   #Authors contributed equally.

Schmidts, A., Marsh, L.C., Srivastava, A.A., Bouffard, A.A., Boroughs, A.C., Scarfò, I., Larson, R.C., Bedoya, F., Choi, B.D., Frigault, M.J., Bailey, S.R., Leick, M.B., Vatsa, S., Kann, M.C., Prew, M.S., Kleinstiver, B.P., Joung, J.K., and Maus, M.V.* Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. J Immunother Cancer. 2020. doi: 10.1136/jitc-2020-000990. PMCID: PMC7477986.

2019

Choi, B.D., Yu, X., Castano, A.P., Darr, H., Henderson, D.B., Bouffard, A.A., Larson, R.C., Scarfò, I., Bailey, S.R., Gerhard, G.M., Frigault, M.J., Leick, M.B., Schmidts, A., Sagert, J.G., Curry, W.T., Carter, B.S., and Maus, M.V.* CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer, 2019. doi: 10.1186/s40425-019-0806-7. PMCID: PMC6857271.

Bowers, J.S., Bailey, S.R., Rubinstein, M.P., Paulos, C.M., and Camp, E.R.* Genomics meets immunity in pancreatic cancer: current research and future directions for pancreatic adenocarcinoma immunotherapy. Oncol Rev., 2019. doi: 10.4081/oncol.2019.430. PMCID: PMC6686121.

Ormhøj, M., Scarfò, I., Cabral, M.L., Bailey, S.R., Lorrey, S.J., Bouffard, A.A., Castano, A.P., Larson, R.C., Riley, L.S., Schmidts, A., Choi, B.D., Andersen, R.S., Cedille, O., Nyvold, C.J., Christensen, J.H., Gjerstorff, M.F., Ditzel, H.J., Weinstock, D.M., Barington, T., Frigault, M.J., and Maus, M.V.* Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without co-targeting CD19. Clin Cancer Res., 2019. doi: 10.1158/1078-0432.CCR-19-1337. PMCID: PMC6891163.

Choi, B.D., Yu, X., Castano, A.P., Bouffard, A.A., Schmidts, A., Larson, R.C., Bailey, S.R., Boroughs, A.C., Frigault, M.J., Leick, M.B., Scarfò, I., Cetrulo, C.L., Demehri, S., Nahed, B.V., Cahill, D.P., Wakimoto, H., Curry, W.T., Carter, B.S., and Maus, M.V.* CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019. doi: 10.10138/s41587-019-0192-1. PMID: 31332324.

Bailey, S.R., and Maus, M.V.* Gene editing for immune cell therapies. Nat Biotechnol., 2019. doi: 10.1038/s41587-019-0137-8. PMID: 31160723.

2018

Knochelmann, H.M., Dwyer, C.J., Bailey, S.R., Amaya, S.M., Elston, D.E., Mazza-McCrann, J.M., and Paulos, C.M.* When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cell Mol Immunol., 2018. doi: 10.1038/s41423-018-0004-4. PMCID: PMC6068176.

2017

Bailey, S.R., Nelson, M.H., Majchrzak, K., Bowers, J.S., Wyatt, M.M., Smith, A.S., Neal, L.R., Shirai, K., Carpenito, C., June, C.H., Zilliox, M.J., and Paulos, C.M.* Human CD26high T cells elicit durable immunity against multiple malignancies via enhanced migration and persistence. Nat Commun. 8(1), 2017. doi: 10.1038/s41467-017-01867-9. PMCID: PMC5719008.

Nelson, M.H., Bowers, J.S., Bailey, S.R., Diven, M.A., Fugle, C.W., Kaiser, A.D., Wrzesinski, C., Liu, B., Restifo, N.P., and Paulos, C.M.* Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning. J Immunother Cancer 4(6), 2017. doi: 10.1186/s40425-016-0110-8. PMCID: PMC4754841.

Bowers, J.S., Majchrzak, K., Nelson, M.H., Aksoy, B.A., Wyatt, M.M., Smith, A.S., Bailey, S.R., Neal, L.R., Hammerbacher, J., and Paulos, C.M.* PI3Kδ inhibition enhances the antitumor fitness of adoptively transferred CD8+ T cells. Front Immunol. 8(1221), 2017. doi: 10.3389/fimmu.2017.01221. PMCID: PMC5626814.

Neal, L.R., Bailey, S.R., Wyatt, M.M., Bowers, J.S., Majchrzak, K., Nelson, M.H., Haupt, C., Paulos, C.M., and Varela, J.C.* The basics of artificial antigen presenting cells in T cell-based cancer immunotherapies. J Immunol Res Ther. 2(1): 68-80, 2017. PMCID: PMC5560309.

Majchrzak, K., Nelson, M.H., Bowers, J.S., Bailey, S.R., Wyatt, M.M., Wrangle, J.M., Rubinstein, M.P., Varela, J.C., Li, Z., Himes, R.A., Chan, S.S., and Paulos, C.M.* b–catenin and PI3Kd inhibition expands precursor Th17 cells with heightened stemness and antitumor activity. JCI Insight 2(8), 2017. doi: 10.1172/jci.insight.90547. PMCID: PMC5396523.

Bowers, J.S., Nelson, M.H., Majchrzak, K., Bailey, S.R., Rohrer, B., Kaiser, A., Atkinson, C., Gattinoni, L., and Paulos, C.M.* Th17 cells are refractory to senescence retaining robust antitumor activity after long-term ex vivo expansion. JCI Insight 2(5), 2017. doi: 10.1172/jci.insight.90772. PMCID: PMC5333954.

Zhu, P., Bailey, S.R., Paulos, C.M., Atkinson, C., and Tomlinson, S.* Targeted complement inhibition protects vascularized composite allografts from acute graft injury and prolongs graft survival when combined with subtherapeutic cyclosporine A therapy. Transplantation 101(4), 2017. doi: 10.1097/TP.0000000000001625. PMCID: PMC5360489.

2016

Nelson, M.H., Bowers, J.S., Bailey, S.R., Diven, M.A., Fugle, C.W., Kaiser, A.D., Wrzesinski, C., Liu, B., Restifo, N.P., and Paulos, C.M.* Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning. J Immunother Cancer 4(6), 2016. doi: 10.1186/s40425-016-0110-8. PMCID: PMC4754841.

Majchrzak, K., Nelson, M.H., Bailey, S.R., Bowers, J.S., Yu, X.Z., Rubinstein, M.P., Himes, R.A., and Paulos, C.M.* Exploiting IL-17-producing CD4(+) and CD8(+) T cells to improve cancer immunotherapy in the clinic. Cancer Immunol Immunother., 65(3):247-59, 2016. doi: 10.1007/s00262-016-1797-6. PMCID: PMC5115162.

2015

Bowers, J.S., Kundimi, S., Nelson, M.H., Bailey, S.R., Huff, L.W., Schwartz, K.M., Cole, D.J., Rubinstein, M.P., and Paulos, C.M.* Dendritic cells in irradiated mice trigger the functional plasticity and antitumor activity of adoptively transferred Tc17 cells via IL12 signaling. Clin Cancer Res. 21(11):2546-57, 2015. doi: 10.1158/0008-5472.CAN-14-1450. PMCID: PMC4452402.

2014

Chatterjee, S., Kesarwani, P., Song, J.H., Thyagarajan, K., Soloshchenko, M., Fu, J., Bailey, S.R., Kraft, A., Paulos, C.M., Yu, X., and Mehrotra, S.* Reducing CD73 expression by IL1β-programmed Th17 cells improves immunotherapeutic control of tumors. Cancer Res. 74(21):6048-59, 2014. doi: 10.1158/0008-5472.CAN-14-1450. PMCID: PMC4216762.

Bailey, S.R., Nelson, M.H., Himes, R.A., Li, Z., Mehrotra, S., and Paulos, C.M.* Th17 cells in cancer: the ultimate identity crisis. Front Immunol. (5)276, 2014. doi: 10.3389/fimmu.2014.00276. PMCID: PMC4060300.